BridgeBio Pharma (BBIO) shares were falling past 5% in recent Thursday trading after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
KKR Genetic Disorder said in the filing that before BridgeBio's initial public offering, it bought about 167.7 million preferred units of BridgeBio for roughly $170.6 million in a series of financing deals.
The preferred units held by KKR Genetic Disorder were converted into about 34.3 million shares of BridgeBio, KKR Genetic Disorder said.
Price: 33.12, Change: -1.86, Percent Change: -5.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。